# Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

> **NCT00469183** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 70 (actual)

## Conditions studied

- Melasma

## Interventions

- **DRUG:** Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%

## Key facts

- **NCT ID:** NCT00469183
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469183, "Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00469183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*